tbuckley/cabot-search huggingface dataset:
Cushing's Syndrome and Corticotropin-Secreting Carcinoma of the Lung
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Test Name
Authors: Claude Matuchansky
Journal: JAMA (2016)

US Preventive Services Task Force; Kirsten Bibbins-Domingo, PhD, MD, MAS; David C. Grossman, MD, MPH; Susan J. Curry, PhD; Karina W. Davidson, PhD, MASc; John W. Epling Jr, MD, MSEd; Francisco A. R. García, MD, MPH; Matthew W. Gillman, MD, SM; Diane M. Harper, MD, MPH, MS; Alex R. Kemper, MD, MPH, MS; Alex H. Krist, MD, MPH; Ann E. Kurth, PhD, RN, MSN, MPH; C. Seth Landefeld, MD; Carol M. Mangione, MD, MSPH; Douglas K. Owens, MD, MS; William R. Phillips, MD, MPH; Maureen G. Phipps, MD, MPH; Michael P. Pignone, MD, MPH; Albert L. Siu, MD, MPH
Three Errors in Medical News &amp; Perspectives Article
Authors: Isabelle Arnulf, Mila Merino-Andreu, Sophie Birolleau, Thomas Similowski, Jean-Philippe Derenne
Journal: JAMA (2002)

trol is unlikely due to the absence of central apneas and the similar OSAS frequency in patients with recent or not recent VTE.We therefore suggest that the OSAS in our patients contributed to rather than resulted from VTE, at least as a cofactor.It is important to note that clinical symptoms failed to discriminate between the 2 groups and are therefore unlikely to be helpful in the screening of patients with VTE for OSAS.Our results need to be confirmed by larger studies.Meanwhile, awareness of an association between these 2 pathologies might influence management in certain clinical situations, such as isolated hypoxemia in obese patients with OSAS.
Erratum
Authors: Ai Mjr, A Anderson, A 4b, E Barnes, J Brown, F Blumer, Stafford ; ', Mr W', P Beaumont, Aylesbury Braidwood, Mr Mbeatty, Mr Bruce, J Brittol, A Boyd, Ware Mr, Lou- Dd Benson, J Brierley, W Cnoltus, Kendal Cooper, C Mr, London Carvell, Mr Cantab, London Carre-Smith, C Clare- Mont, E Cooke, A Churchill, London Civis, B Eaton, G Crowe, Worcester Correspondent, F Coutts, M Dockrell, A Davies, Messrs Down 'broe, Mr Edwards, Shrewsbury Edwards, F Eurich, Elberfeld Farben, Fabriken Co, W Bemetson, W Forbes-Leslie, Johnsou Assett, A Glregor, B Garrett, W Kingston, Brighton Griffin, J Gem- Mell, A Liveipool, B Holt,-Iortland, U Mr, D Headridge, T Hyslop, T Hime, W Ilorrocks, Bradford; -Mr. -T Hordert, Cardiff Mr, S Harris, Walsall Hawley, F Howes, Lincoln Mr, A Judson, New York, Mr Job, Mr Rt, Peter- | Borouilr Rr Jolly, J Lynch, Mr Lunt, P Leech, E Lermitte, J Little, W Lattey, Southam Ims, R Meade-King, Hove Amedcalf, Mt -Iackenzie, C Marshall, London Mex, ; Mac- Nicol, G Mcelligott, Mr Murray, E Nason, ) Messrs, Sonand Oppenheimer, London Old, Mr Palmer, London Rendle, S Os's, C Reinhardt, St Roberts, J Albans, Staines Scutt, E Solly, ; Stoker, R Shaw, H Smith, A Swallow, ; Stephenson
Journal: BMJ (1898)

write to say that detailed information on this point can be obtained by consulting the Priced Vocabulary of Stores, which can be obtained at any Government publishers.The newest pattern (Mark V) ambulance wagon costs about £T43, accommodates twelve persons, but would re- quire four horses to draw it.The ambulance carts are much lighter, and will carry four patients sitting or two recumbent, the cost of Mark II being about £94.It should be remembered that none but the strongest wagons or carts will bear the strain of manceuvres over rough or broken ground.
Undocumented HIV Infection
Authors: Donald E. Craven
Journal: Annals of Internal Medicine (1995)

Letters15 September 1995Undocumented HIV InfectionDonald E. Craven, MD, Kathleen A. Steger, RN, MPH, and David Allen, BADonald E. Craven, MDBoston City Hospital; Boston, MA 02118Search for more papers by this author, Kathleen A. Steger, RN, MPHBoston City Hospital; Boston, MA 02118Search for more papers by this author, and David Allen, BABoston City Hospital; Boston, MA 02118Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-6-199509150-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We concur with Dr. Harrow's comments underscoring the need to carefully evaluate prisoners with undocumented HIV infection for malingering and to subsequently carefully document HIV status. We add another note of caution, however, regarding intravenous drug users. We know of two such patients who gave their hospital cards to a known HIV-infected person to have an HIV antibody test drawn in the hospital's central phlebotomy laboratory.Andrews and coworkers raise several issues regarding the data and conclusions from our recent article [1]. In reference to the case–control study design, we also have concerns about self-reported data, but the ...References1. Craven DE, Steger KA, La Chapelle R, Allen DM. Factitious HIV infection: the importance of documenting infection. Ann Intern Med. 1994; 121:763-6. Google Scholar2. Byland DR, Ziegner UH, Hooper DG. Review of testing for human immunodeficiency virus. Clin Lab Med. 1992; 12:305-33. Google Scholar3. Duncan RA, von Reyn CF, Alliegro GM, Toossi Z, Sugar AM, Levitz SM. Idiopathic CD4+ T-lymphocytopenia—four patients with opportunistic infections and no evidence of infection. N Engl J Med. 1993; 328:393-8. Google Scholar Author, Article, and Disclosure InformationAuthors: Donald E. Craven, MD; Kathleen A. Steger, RN, MPH; David Allen, BAAffiliations: Boston City Hospital; Boston, MA 02118 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 September 1995Volume 123, Issue 6Page: 470-471KeywordsAddictsHIVHIV infectionsHealth care providersLymphocytesPerceptionPhlebotomyResearch laboratories ePublished: 15 August 2000 Issue Published: 15 September 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Missing Line
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of gemcitabine-platinum (Gem-P) in patients with advanced gall bladder (GB) cancer: A more aggressive disease compared to the West Tata Memorial Centre (TMC) experience.
Authors: Bhawna Sirohi, Vipul Sheth, Ashish Singh, Mukta Ramadvar, Vikas Otswal, Mahesh Goel, Shailesh V. Shrikhande
Journal: Journal of Clinical Oncology (2014)

e15145 Background: GB cancer is a common cancer in northern India. Gem-P is currently the standard of care for pts with advanced biliary tract cancers based on the ABC02 study which had 61 pts with GB cancer with a clinical benefit rate (CR+PR+SD) of 85%. Indian patients have a higher risk disease and present at a more advanced stage than in the West and data on treatment is lacking. Methods: This is retrospective analysis of the prospectively maintained database of 131 pts with advanced GB cancer treated at TMC between Jan 2012-May 2013. Aim of the study is to assess the clinical benefit rate in this group of pts with the Gem-P. Pts received cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on D1 and D8 of a 21day cycle, for gem-oxaliplatin, pts received gemcitabine 1000mg/m2 on D1 and oxaliplatin 100mg/m2 on D2 every 14 days. Response was assessed after 3-4 cycles. Results: Of the 131 patients, 110 pts were treated with Gem-P (95 oxaliplatin, 15 cisplatin; 1 received cetuximab-Gem-P) and 21 (16%) pts received best supportive care alone in view of poor performance status and deranged organ function. Median age was 53 years (range, 27-76), 82F/49 M; median CA19.9 206 (<2-2251660); median CEA 6.9 (0.8-3541); site of metastases was liver in 66 (50%), nodal in 74(56%), peritoneal in 29(22%) and bilateral ovarian in 5(3.8%) patients. Of the 110 pts treated with GEM-P, PS was 0-1 in 91% of patients; median number of cycles received was 4 (1-12); grade 3 &4 toxicities were- thrombocytpenia-12 (11%), neutropenia -2 (2%), hepatitis -2 (2%) patients, neuropathy-4 (4%) and diarrhea-8 (7.2%). 98 /110 were evaluable for response out of which 8 (7%) had CR, 26 (24%) had PR, 9 (8%) had SD, and 55 (50%) had progressive disease. The median OS was 8 months and PFS was 5 months. 45/81 pts (56%) pts received 2nd-line chemotherapy (majority capecitabine -irinotecan based). Conclusions: This is the single largest study to show tolerance and efficacy of Gem-P in Indian pts with advanced GB cancer. Compared to the ABC 02 study, the clinical benefit rate is low at 39% suggesting that the biology of advanced GB cancers in Indian pts is likely to be aggressive and needs to be studied in prospectively designed studies.
Fourth International Symposium on Nasopharyngeal Carcinoma
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article Fourth International Symposium on Nasopharyngeal Carcinoma Get access JNCI: Journal of the National Cancer Institute, Volume 69, Issue 1, July 1982, Page 317, https://doi.org/10.1093/jnci/69.1.317-d Published: 01 July 1982
Post-marketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials.
Authors: Daniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, Consolacion Molto, Alberto Ocana, Bostjan Seruga, Eitan Amir
Journal: Journal of Clinical Oncology (2018)

e18717 Background: Modifications in cancer drug indications, dosing, and related toxicities following Food and Drug Administration approval are common. It is unclear if drug approval without a supporting randomized controlled trial (RCT) influences the probability of such modifications. Methods: We searched the Drugs@FDA website for new drug indications for solid tumors approved from January 2006 to December 2016. Study characteristics, regulatory pathways and label modifications from approval to October 2017 were collected from drug labels. Label modifications were considered to be major if defined as such in the drug label and if constituted a clinically meaningful change. Indications approved with and without supporting RCTs were compared using logistic regression. Results: We identified 59 individual drugs for 109 solid tumor indications. Of these, 17 indications (15.6%) were not supported by a RCT and were more likely to involve small molecules or immunotherapy (OR 2.78, 95% CI 0.98-7.69, p = 0.05, p = 0.05), to require companion diagnostic tests (OR 3.9, 95% CI 1.27-11.96, p = 0.02), to include surrogate endpoints as the primary outcome (100% vs. 51%, OR 7.88, 95% CI 2.78-22.78, p < 0.001) and to receive breakthrough therapy designation (OR 7.62, 95% CI 1.77-32.80, p = 0.006) or accelerated approval (OR 17.67, 95% CI 5.22-59.78, p < 0.001). Indications not supported by RCTs were associated with an increase in the odds of post-approval modifications in common adverse events (71% vs. 29%, OR 5.78, 95% CI 1.86-17.99, p = 0.002) and a borderline significant increase in the odds of post-approval major modifications in warnings and precautions (88% vs. 62%, OR 4.91, 95% CI, 0.99-21.36, p = 0.051). Post-approval major modifications in indication and usage, dosing and administration, boxed warnings and contraindications were comparable between both groups. Conclusions: Cancer drug indications not initially supported by RCTs are associated with more post-marketing safety-related label modifications. Healthcare professionals should be vigilant for unrecognized side effects when prescribing drugs approved without a supporting RCT.
Further Experience with Colchicine in Treatment of Sarcoid Arthritis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interaction between Cadmium and Selenium in Rat Plasma
Authors: T. A. Gasiewicz, J. C. Smith
Journal: Environmental Health Perspectives (1978)

The metabolism of 75Se-labeled SeO32− and its conversion by intact rat erythrocytes in vitro to a form which complexes with Cd and plasma proteins were studied. By utilizing both excess SeO32− and N-ethylmaleimide to lower erythrocyte reduced glutathione (GSH) concentrations, it was shown that the uptake and metabolism of SeO32− were GSH-dependent, the probable intermediate being glutathione selenotrisulfide (GSSeSG). Secondary release of selenium by rat erythrocytes had no relation to the erythrocyte transport of oxidized glutathione (GSSG). While fluoride depressed and chromate increased GSSG transport, chromate, a glutathione reductase inhibitor, decreased selenium release. This release appeared to be secondary to a reaction catalyzed by glutathione reductase. The similarity of I50 values for chromate's inhibition of glutathione reductase and for the inhibition of selenium release further suggested a relationship between these two events. H2Se or a similar product of GSSeSG reduction is proposed to be the active product of SeO32− metabolism by rat erythrocytes. By use of gel-filtration and ion-exchange methods it was noted that the incubation of H2Se with cadmium and plasma produced a Cd–Se complex indistinguishable from that produced by incubation of Cd, SeO32−, plasma, and erythrocytes in vitro, or that noted following the administration of Cd and SeO3 in vivo. A mechanism whereby the tissue distribution and toxicity of cadmium are altered by selenium is suggested.
ABSTRACTS
Authors: Ernst Jaffe, Abstracters Barkhan, T Bothwell, T Brittingharn, Jacque Caen, B Chatterjea, Pietro Denicola, Ludvik Donner, A Erslev, Philadelphia Fudenberg, San Francisco, Katsuhiro Fukutake, Robert Goldstein, Ira Green, York City, F Gunz, New Zealand, N Of, R Briggs, P Perillie, S Finch, R Lewis, J Sutton, L Weiss, D Beale, H Lehmann, A Drury, E Tucker
Journal: Blood (1966)
Does This Patient Have Sinusitis?
Authors: Lawrence J. Gordon
Journal: JAMA (1994)

<h3>To the Editor.</h3> —The review and study by Williams and Simel<sup>1</sup>is an admirable attempt to answer the often-asked question, "Does this patient have sinusitis?" This is a problem that most primary care physicians should be prepared to deal with and treat appropriately. I have several concerns with the facts as stated in this article. The authors state that sinus aspiration and culture is the "gold standard"; however, this is not often used because of the difficulty in obtaining a specimen and the difficulty in culturing the anaerobic bacteria responsible for much of chronic sinusitis. They in turn refer to sinus roentgenograms as a readily obtained and pragmatic reference standard. A four-view sinus series may be useful as an adjunct to the clinical examination in diagnosing acute sinusitis, especially acute frontal sinusitis. However, because of the often-reported discordance between plain films and sinus computed tomography (CT)<sup>2-4</sup>(the accepted
Abstract 3277: Withdrawal of a Technology-Based Daily Weight Monitoring System in Patients with Advanced Heart Failure Eliminates Mortality Benefit
Authors: Niya A Jones, David S Frankel, John D Piette, Lee R Goldberg
Journal: Circulation (2007)

Background: Heart failure (HF) is a common, costly cause of hospitalization. Few studies have evaluated the long-term impact of electronic disease management (EDM) on HF care. We reported a mortality benefit among HF patients (pts) undergoing electronic daily weight assessment in the Weight Monitoring in Heart Failure (WHARF) trial. Using trial data on transplant-free survival, we evaluated whether the initial mortality benefit persisted after withdrawal of the EDM system. Methods: 280 pts from 16 HF centers in the US were randomized, during admission for NYHA III/IV HF, to receive usual HF care or HF care and the AlereNet TM system (Alere Medical, Reno, NV). Pts were followed for 6 months prior to removal of the system. Transplant-free mortality data were then examined over the next 50 months. Results: 138 pts received the EDM system and 142 received usual care. Mean age was 59+/−15 years; 68% male; 64% Caucasian; 75% had NYHA III HF. A 56.2% reduction in mortality was demonstrated for pts randomized to the EDM group (p&lt;0.003). Continued Kaplan-Meier analysis, however, ultimately showed a withdrawal effect among those in this group. By approximately 8 months after removal of the EDM system, mortality rates between the groups were identical. In the early withdrawal phase, mortality among those removed from the technology appears higher. (Figure 1 ) Conclusions: The mortality benefit in the intervention arm did not persist on cessation of the EDM system. This withdrawal effect further supports the notion that technology-based weight monitoring offsets mortality among those with advanced HF. Additional research is warranted to determine the optimal duration of such EDM in HF care.
THE JOURNAL AND ITS ADVERTISING POLICY.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Lymphatic System in Health and Disease
Journal: BMJ (1940)

The lymphatic vascular system has an important role in the regulation of tissue pressure, immune surveillance and the absorption of dietary fat in the intestine.There is growing evidence that the lymphatic system also contributes to a number of diseases, such as lymphedema, cancer metastasis and different inflammatory disorders.The discovery of various molecular markers allowing the distinction of blood and lymphatic vessels, together with the availability of a increasing number of in vitro and in vivo models to study various aspects of lymphatic biology, has enabled tremendous progress in research into the development and function of the lymphatic system.This review discusses recent advances in our understanding of the embryonic development of the lymphatic vasculature, the molecular mechanisms mediating lymphangiogenesis in the adult, the role of lymphangiogenesis in chronic inflammation and lymphatic cancer metastasis, and the emerging importance of the lymphatic vasculature as a therapeutic target.
Course of Immunity to Diphtheria Based on Study of Schick Test in 1,516 Vaccinated Children and Adolescents
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal